Tag Archives: pharmaceutical

Research and Markets: Personalized Medicine – Scientific and Commercial Aspects – Updated 2013 Report

Posted on by

DUBLIN–(BUSINESS WIRE)– Research and Markets (http://www.researchandmarkets.com/research/c247cv/personalized) has announced the addition of Jain PharmaBiotech’s new report “Personalized Medicine – Scientific and Commercial Aspects” to their offering. The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics Continue reading →

China Chinese Patent Medicine Industry Report, 2012-2015

Posted on by

NEW YORK, April 22, 2013 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: China Chinese Patent Medicine Industry Report, 2012-2015 http://www.reportlinker.com/p0361703/China-Chinese-Patent-Medicine-Industry-Report-2012-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication In recent years, China’s Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012 at a CAGR of 26.2%. Over the same period, the total profit maintained a CAGR of 26.6%, and the gross margin remained higher than the average level of the overall pharmaceutical industry. In succession to the Opinions on Promoting the Development of Traditional Chinese Medicine Services and Trade, the Twelfth Five-Year Plan on the Development of Traditional Chinese Medicine and other favorable policies, the new National Essential Drugs List published in March 2013 increased the number of Chinese patent medicine from 102 in 2009 to 203, and the proportion in total quantity from 33% to 39%. Continue reading →

Research and Markets: Personalized Medicine – Scientific and Commercial Aspects – 2013 Report

Posted on by

DUBLIN–(BUSINESS WIRE)– Research and Markets (http://www.researchandmarkets.com/research/vkkh7b/personalized) has announced the addition of Jain PharmaBiotech’s new report “Personalized Medicine – Scientific and Commercial Aspects” to their offering. The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics Continue reading →

Foundation Medicine Appoints Steven J. Kafka, Ph.D. as Chief Business Officer

Posted on by

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced the appointment of Steven J. Kafka, Ph.D. Continue reading →

Bharat Book Presents: China Genetic Engineering Drug Industry Report, 2011-2012 – Video

Posted on by




Bharat Book Presents: China Genetic Engineering Drug Industry Report, 2011-2012 For more information kindly visit on: www.bharatbook.com China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. Continue reading →

Nonviral Vectors for – Video

Posted on by




Nonviral Vectors for Buy from Amazon CA Site www.amazon.ca Product Description Nonviral Vectors for Gene transfer within humans has been an obstacle until about 10 years ago. At that time, it was found that viral vectors were effective carriers of “healthy genes” into patients' cells Continue reading →

Critical Outcome Technologies Inc. Announces Drug Discovery Agreement With Multinational Pharmaceutical Company

Posted on by

LONDON, ONTARIO–(Marketwire – Dec 6, 2012) – Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that it has entered into a drug discovery agreement with a multinational pharmaceutical company whereby COTI will use its proprietary artificial intelligence drug discovery system, CHEMSAS, to identify and optimize a number of small molecules against a target of commercial interest to the pharmaceutical company. Continue reading →

Emotional Activation from Theory to Practice – Video

Posted on by




Emotional Activation from Theory to Practice Yves Furet and Daniel Baumgartner, partners at LeadX, introduce the Betaferon case: possibly the clearest piece of evidence that the emotional-activation approach works in the pharmaceutical world. Betaferon is the first ever multiple sclerosis medicine. Continue reading →

My Weight Loss Journey May Inspire You, Don’t Miss It-Watch it – Video

Posted on by




My Weight Loss Journey May Inspire You, Don't Miss It-Watch it►►tinyurl.com►►tinyurl.com►►tinyurl.com out and add some! . You can also watch events on Help com as they happen. Continue reading →

Merck Serono Advances to Eighth Place in the 2012 Access to Medicine Index

Posted on by

GENEVA, November 28, 2012 /PRNewswire/ — Merck Serono, a division of Merck, Darmstadt, Germany, announced today it now ranks eighth in the Access to Medicine Index published today by the Access to Medicine Foundation. Mercks access to medicine activities are conducted through its pharmaceuticals division, Merck Serono, and integrated into the companys Corporate Responsibility strategy. Merck Serono has moved up nine places compared to the 2010 ranking Continue reading →

Medicine overuse is a bitter pill to swallow

Posted on by

According to the National Health Insurance Fund, Hungarians rank third in Europe when it comes to unnecessary medicine use, and while the market has similar notions, professionals emphasize that there is no clear-cut definition as to which medicines qualify as unnecessary or redundant. Continue reading →

Liberal group outlines $385B in Medicare cuts

Posted on by

WASHINGTON (AP) Hoping to head off wider health care cuts in upcoming budget talks, a think tank close to the White House is unveiling a plan for how to save $385 billion, mostly from Medicare. Medicaid and the new health care law are largely spared from cuts in the blueprint being released Wednesday by the liberal-leaning Center for American Progress. Instead, it targets Medicare service providers, from the pharmaceutical industry to hospitals and nursing homes. Continue reading →

Saudi- KACST conducted 193 research projects on nanotechnology in four years

Posted on by

(MENAFN – Arab News) During a period of four years ending in 2011, King Abdulaziz City for Science and Technology (KACST) conducted 193 research projects in the field of nanotechnology. These cost SR 574 million, said KACST President Mohammed bin Ibrahim Alsuwaiyel yesterday. Alsuwaiyel inaugurated the second Saudi International Nanotechnology Conference at KACST headquarters in Riyadh. Continue reading →

KACST conducted 193 research projects on nanotechnology in four years

Posted on by

RIYADH: During a period of four years ending in 2011, King Abdulaziz City for Science and Technology (KACST) conducted 193 research projects in the field of nanotechnology. These cost SR 574 million, said KACST President Mohammed bin Ibrahim Alsuwaiyel yesterday Continue reading →

Dendritic Cells: Biology And Clinical Applications – Video

Posted on by




Dendritic Cells: Biology And Clinical Applications ll4.me Dendritic Cells: Biology And Clinical Applications Dendritic Cells, 2nd Edition is the new edition of the extremely successful book published in 1998. With the volume of literature on dendritic cells doubling every year, it is almost impossible to keep up. This book provides the most up-to-date synthesis of the literature, written by the very best authors Continue reading →

Research and Markets: Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area …

Posted on by

DUBLIN–(BUSINESS WIRE)– Research and Markets (http://www.researchandmarkets.com/research/kknlff/therapeutic) has announced the addition of Woodhead Publishing Ltd’s new book “Therapeutic antibody engineering: Current and future advances driving the strongest growth area in the pharmaceutical industry” to their offering. Continue reading →

Stem cell researchers discuss latest discoveries at the New York Stem Cell Foundation Conference

Posted on by

Public release date: 10-Oct-2012 [ | E-mail | Share ] Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation NEW YORK, NY (October 10, 2012) Leaders in translational stem cell research from across the country and around the world will present findings on how advances in stem cell science lead to better treatments and cures to disease and injury at The New York Stem Cell Foundation’s Seventh Annual Translational Stem Cell Research Conference, held at The Rockefeller University in Manhattan on October 10-11. Today, a series of panels, oriented towards a lay audience, will focus on how stem cells may be implemented for disease modeling and applied in the development of targeted drugs and treatments for major diseases and injuries. Continue reading →